{"commentary":{"count":26,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":13,"youtube":9,"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06417814\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"TROPION-Lung15","nct_id":"NCT06417814","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tropion-lung15-nct06417814. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"TROPION-Lung15","arms":[{"description":"Participants will receive Dato-DXd 6 milligrams per kilogram (mg/kg) as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of every 21-day cycle, and osimertinib 80 milligrams (mg) once daily (QD) orally, until RECIST v1.1-defined radiological progression by investigator, unacceptable toxicity, or other discontinuation criterion is met.","label":"Group 1: Dato-DXd + Osimertinib Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants will receive Dato-DXd 6 mg/kg as IV infusion Q3W on Day 1 of every 21-day cycle, until RECIST v1.1-defined radiological progression by investigator, unacceptable toxicity, or other discontinuation criterion is met.","label":"Group 2: Dato-DXd Monotherapy","type":"EXPERIMENTAL"},{"description":"Participants will receive pemetrexed 500 milligrams per meter square (mg/m2) in combination with carboplatin (AUC5) or cisplatin 75 mg/m2 as IV infusion Q3W for 4 cycles followed by pemetrexed maintenance 500 mg/m2 as IV infusion Q3W, until RECIST v1.1-defined radiological progression by investigator, unacceptable toxicity, or another discontinuation criterion is met.","label":"Group 3: Platinum-based Doublet Chemotherapy","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2028-09-27","type":"ESTIMATED"},"conditions":["Metastatic Non-small Cell Lung Cancer"],"enrollment":{"count":744,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Dato-DXd","type":"DRUG"},{"name":"Osimertinib","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"}],"last_update":"2026-05-14","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free Survival (PFS)","timeFrame":"Up to 2.5 years"}],"references":[{"citation":"Tan DS, Nadal E, Cheema P, Wu YL, Ahn MJ, Tanizaki J, Grainger E, Nizialek E, Forcina A, van der Gronde T, Yu HA. TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib. Ther Adv Med Oncol. 2025 Dec 23;17:17588359251385410. doi: 10.1177/17588359251385410. eCollection 2025.","pmid":"41466843","type":"DERIVED"}],"start_date":{"date":"2024-10-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06417814"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tropion-lung15-nct06417814"}